On November 1, 2024 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported that company management will participate in three upcoming investor conferences in November (Press release, Adicet Bio, NOV 1, 2024, View Source [SID1234647644]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Truist Securities BioPharma Symposium, November 7, 2024, New York, NY

Members of management will be available for 1×1 meetings on November 7, 2024
Guggenheim Securities Healthcare Innovation Conference, November 11-13, 2024, Boston, MA

Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 12, 2024 at 3:00 p.m. ET
Jefferies London Healthcare Conference, November 19-21, 2024, London

Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 19, 2024 at 12:30 p.m. BST
The live audio webcasts of the fireside chats can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.